Fulgent Genetics, Inc. Earnings Recaps
Fulgent Genetics shares dropped 15.7% after the quarter as investors reacted negatively to significant deceleration in the core Precision Diagnostics segment, coupled with continued operational challenges in revenue recognition that pressured near-term revenue visibility and margins.
Key takeaways
- Laboratory services revenue grew 4% year-over-year to $85.4 million, boosted by recent acquisitions Bako and StrataDX.
- Precision Diagnostics revenue declined 13% year-over-year to $41.5 million, highlighting a key business segment weakness.
- Sequential revenue in Precision Diagnostics increased 3%, but ongoing issues in billing and revenue cycle management delayed claim processing and reduced recognized revenue.
- Management prioritized resolving revenue cycle inefficiencies but provided a cautious outlook given these operational headwinds.
- Encouraging progress in the therapeutic development pipeline, including completion of Phase II data for FID-007 and advancement of FID-022 to Phase I dose escalation, but these remain early-stage with no near-term revenue impact.
Fulgent Genetics shares fell 7.0% post-earnings as investors reacted to a notable sequential revenue decline and soft performance in the laboratory services segment, driven by the loss of a major customer. While management reiterated full-year revenue guidance and highlighted progress in therapeutic development, the quarter's deceleration and updated EPS guidance disappointed expectations.
Key takeaways
- Q1 revenue came in at $71.1 million, representing a 3.2% year-over-year decrease and a sharper 14.6% decline sequentially, with the drop primarily attributed to a large customer insourcing testing.
- Management maintained full-year 2026 revenue guidance but adjusted non-GAAP EPS and cash balance outlook due to share repurchases.
- The laboratory service business struggled this quarter despite recent acquisitions (Bako Diagnostics and StrataDx), underscoring segment-specific pressures.
- Therapeutic development advanced, with FID-007 enrollment for Phase II trial completed on schedule and a Phase III program targeted for 2027.
- Management continues to point to AI and digital pathology investments as long-term growth drivers, though near-term headwinds weighed on the quarter’s results.
Fulgent Genetics reported strong third-quarter results for 2025, showcasing robust growth in laboratory services and significant progress in its therapeutic development pipeline.
Key takeaways
- Laboratory services revenue reached nearly $84 million, with a year-over-year growth of 16.4% driven by the Precision Diagnostics and Biopharma segments.
- Fulgent is raising its outlook for 2025, reflecting sustained business momentum and successful integration of AI technologies in its operations.
- Phase II trials for lead candidate FID-007 demonstrated meaningful efficacy in treating recurrent or metastatic head and neck cancer, with overall response rates of 51%.
- FID-022 has entered Phase I trials, targeting multiple solid tumors, indicating an expanding and diversified pipeline.
- The company continues to enhance diagnostic services, recently launching a rapid whole genome sequencing offering that provides preliminary results within 48 hours.